A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Inclusion Criteria:

1. Participant has regular menstrual cycles ≥24 days and ≤34 days

2. A minimum 1-year history of migraine (with or without aura) consistent with adiagnosis according to the International Classification of Headache Disorders, 3rdEdition

3. A history of menstrual migraine attacks of at least 3 months

4. Participant reported history of experiencing at least 1 migraine attack during theperimenstrual period in at least 2 out of 3 menstrual cycles immediately prior toscreening.

5. If the participant is receiving a permitted background continuous prophylacticmigraine medication, the medication dose must be stable for at least 3 months priorto the Screening visit and, the dose is not expected to change during the course ofthe study

Exclusion Criteria:

1. Greater than 6 migraine days per month that are outside of the perimenstrual periodin the 3 months prior to Screening

2. A diagnosis of chronic migraine or a history of more than 14 headache days per monthon average, in the 3 months prior to Screening

3. History of retinal migraine, basilar migraine or hemiplegic migraine

4. Current diagnosis of schizophrenia, bipolar, or borderline personality disorder

5. Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), orsignificant neurological disorders (other than migraine), or other medicalconditions (including endocrine and gynecological eg, severe dysmenorrhea